# Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

> **NCT02796937** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Grifols Therapeutics LLC** · enrollment: 290 (estimated)

## Conditions studied

- Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

## Interventions

- **BIOLOGICAL:** Alpha-1 MP

## Key facts

- **NCT ID:** NCT02796937
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2016-07
- **Primary completion:** 2028-09
- **Final completion:** 2029-02
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02796937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02796937, "Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02796937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*